Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of FMT in HSCT Recipients
NCT02733744Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in graft-versus-host disease (GVHD) and Infection, sponsored by Massachusetts General Hospital. Primary endpoint: Feasibility of FMT at 2 days. Started May 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
graft-versus-host disease (GVHD)Infection
Beyond the preview
Go deeper on NCT02733744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733744.